Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 461 Neoplasms 378 Carcinoma, Non-Small-Cell Lung 354 Prostatic Neoplasms 294 Colorectal Neoplasms 257 Lung Neoplasms 225 Multiple Myeloma 206 Neoplasm Metastasis 164 Pancreatic Neoplasms 156 Leukemia, Myeloid, Acute 153 Ovarian Neoplasms 136 Squamous Cell Carcinoma of Head and Neck 130 Melanoma 116 Carcinoma, Renal Cell 103 Stomach Neoplasms 102 Carcinoma, Hepatocellular 100 Recurrence 98 Lymphoma 94 Precursor Cell Lymphoblastic Leukemia-Lymphoma 92 Head and Neck Neoplasms 91 Lymphoma, Non-Hodgkin 86 Glioblastoma 85 Brain Neoplasms 84 Hematologic Neoplasms 83 Urinary Bladder Neoplasms 82 Triple Negative Breast Neoplasms 81 Endometrial Neoplasms 80 Lymphoma, Large B-Cell, Diffuse 79 Leukemia, Lymphocytic, Chronic, B-Cell 77 Uterine Cervical Neoplasms 74

Interventions

Acceptance and Commitment Therapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Substance-Related Disorders × 30 days × Clear all

NCT05643027 2026-05-14

ACTION

Dana-Farber Cancer Institute

Phase NA Completed

Neoplasms, Substance-Related Disorders

Data powered by HemOnc (CC BY 4.0) Colophon ⚡